Alcon announces BRYTLY approval as Alcon stock enters review
Published on 10/17/2026 at 11:15 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSProduct approval and next session
- Alcon announced FDA approval for BRYTLY on October 16, 2026.
- The next Xetra session is scheduled for October 19, 2026.
- BRYTLY is designed to reduce redness for up to 12 hours.
- The product is expected at major retailers in the coming months.
Alcon announced on October 16, 2026, that the U.S. Food and Drug Administration had approved BRYTLY Redness Reliever Eye Drops. The Business Wire release said the product is intended to reduce eye redness and is expected to become available at major retailers and online in the coming months.
Weekend trading
The euro quote for Alcon was not carried into the current weekend session in the retrieved Lang & Schwarz data. The next price is shown from the start of trading by the continuously updated real-time quote of Alcon stock.
Market context: Market report SMI.
BRYTLY product details
According to the Business Wire release, BRYTLY works in one minute and delivers up to 12 hours of whiter-looking eyes. The release also said the product lasts up to 50 percent longer than Lumify, based on the cited label claims.
Next Xetra session
The next Xetra session falls on October 19, 2026. Alcon’s announced product availability is expected in the coming months, according to the Business Wire release.
